Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Cellectar Biosciences, Inc. (CLRB) had Return on Tangible Equity of -89.53% for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
-- |
|
$-5.45M |
|
-- |
|
-- |
|
$6.04M |
|
$-6.04M |
|
$0.59M |
|
$-5.45M |
|
$-5.95M |
|
$-5.45M |
|
$-5.45M |
|
$-5.45M |
|
$-5.95M |
|
$-6.04M |
|
$-5.98M |
|
1.61M |
|
1.61M |
|
$-3.39 |
|
$-3.39 |
|
| Balance Sheet Financials | |
$12.62M |
|
$0.65M |
|
$1.08M |
|
$13.70M |
|
$5.87M |
|
-- |
|
$1.74M |
|
$7.61M |
|
$5.56M |
|
$6.08M |
|
$6.08M |
|
1.81M |
|
| Cash Flow Statement Financials | |
$-14.50M |
|
-- |
|
$2.25M |
|
$23.29M |
|
$11.04M |
|
$-12.25M |
|
$1.13M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.15 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-14.50M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-97.91% |
|
|
Return on Tangible Equity |
-89.53% |
-39.78% |
|
-89.53% |
|
$3.36 |
|
$-9.01 |
|
$-9.01 |
|